Pneumococcal conjugate vaccines - Implications for community antibiotic prescribing

Tina Quanbee Tan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Infections caused by Streptococcus pneumoniae are a major cause of morbidity and mortality in the pediatric population worldwide. Development of increasing resistance to multiple classes of antibiotics is making treatment of infections caused by this organism much more difficult. In order to prevent disease, a 23-valent pneumococal polysaccharide vaccine is available. However, this vaccine is poorly immunogenic in infants and young children. The development and licensing of pneumococcal conjugate vaccines that are safe and effective in the pediatric population is an important step in our ability to decrease the prevalence of pneumococcal disease seen.

Original languageEnglish (US)
Pages (from-to)502-507
Number of pages6
JournalCurrent Opinion in Microbiology
Issue number5
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Pneumococcal conjugate vaccines - Implications for community antibiotic prescribing'. Together they form a unique fingerprint.

Cite this